MGL ligand expression is correlated to BRAF mutation and associated with poor survival of stage III colon cancer patients

Oncotarget

Volumn 6, Issue 28, 2015, Pages 26278-26290

  Lenos, Kristiaan ^a,b   Goos, Jeroen A C M ^a   Vuist, Ilona M ^a,c   den Uil, Sjoerd H ^a,d   Delis van Diemen, Pien M ^a,e   Belt, Eric J Th ^f   Stockmann, Hein B A C ^d   Bril, Herman ^d   de Wit, Meike ^a,e   Carvalho, Beatriz ^a,e   Giblett, Susan ^g   Pritchard, Catrin A ^g   Meijer, Gerrit A ^a,e   van Kooyk, Yvette ^a   Fijneman, Remond J A ^a,e   van Vliet, Sandra J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d Department of Orthopaedic Surgery   (Netherlands)

^e NETHERLANDS CANCER INSTITUTE   (Netherlands)

^f ERASMUS MEDICAL CENTER   (Netherlands)

^g UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

BRAF; C type lectin; Colorectal cancer; Glycosylation; MGL

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; B RAF KINASE INHIBITOR; GLUTAMIC ACID; GLYCAN DERIVATIVE; LECTIN; LIGAND; MACROPHAGE GALACTOSE TYPE LECTIN LIGAND; UNCLASSIFIED DRUG; VALINE; BRAF PROTEIN, HUMAN; MGL LECTIN, HUMAN; TUMOR MARKER;

ADJUVANT THERAPY; ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE FREE SURVIVAL; EPITHELIUM CELL; FEMALE; GASTROINTESTINAL TRACT; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; PREDICTIVE VALUE; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; RECEIVER OPERATING CHARACTERISTIC; RECURRENCE RISK; REFERENCE VALUE; ANIMAL; COLORECTAL NEOPLASMS; DISEASE COURSE; ENZYMOLOGY; GENETIC PREDISPOSITION; GENETICS; HT-29 CELL LINE; IMMUNOLOGY; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; PHENOTYPE; PROPORTIONAL HAZARDS MODEL; SIGNAL TRANSDUCTION; TIME FACTOR; TRANSGENIC MOUSE; TREATMENT OUTCOME; TUMOR ESCAPE; UPREGULATION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HT29 CELLS; HUMANS; KAPLAN-MEIER ESTIMATE; LECTINS, C-TYPE; LIGANDS; MALE; MICE, TRANSGENIC; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PHENOTYPE; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS B-RAF; SIGNAL TRANSDUCTION; TIME FACTORS; TREATMENT OUTCOME; TUMOR ESCAPE; UP-REGULATION;

EID: 84944455052     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4495     Document Type: Article

References (46)

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136:E359-E386.
2. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012; 487:330-337.
3. Ogino S, Galon J, Fuchs CS, Dranoff G. Cancer immunology- analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol. 2011; 8:711-719.
4. Venderbosch S, Nagtegaal ID, Maughan TS, Smith CG, Cheadle JP, Fisher D, Kaplan R, Quirke P, Seymour MT, Richman SD, Meijer GA, Ylstra B, Heideman DA, et al. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res. 2014; 20:5322-5330.
5. Samowitz WS, Sweeney C, Herrick J, Albertsen H, Levin TR, Murtaugh MA, Wolff RK, Slattery ML. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res. 2005; 65:6063-6069.
6. Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, Dietrich D, Biesmans B, Bodoky G, Barone C, Aranda E, Nordlinger B, Cisar L, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol. 2010; 28:466-474.
7. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144:646-674.
8. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006; 313:1960-1964.
9. Steinberg SM, Zhang P, Malik B, Boni A, Shabaneh T, Byrne K, Mullins DW, Brinckerhoff CE, Ernstoff M, Bosenberg MW, Turk MJ. BRAF-inhibition alleviates immune suppression in murine autochthonous melanoma. Cancer Immunol Res. 2014; 2:1044-1050.
10. Boland CR, Deshmukh GD. The carbohydrate composition of mucin in colonic cancer. Gastroenterology. 1990; 98:1170-1177.
11. Itzkowitz SH, Yuan M, Montgomery CK, Kjeldsen T, Takahashi HK, Bigbee WL, Kim YS. Expression of Tn, sialosyl-Tn, and T antigens in human colon cancer. Cancer Res. 1989; 49:197-204.
12. van Vliet SJ, van Liempt E, Saeland E, Aarnoudse CA, Appelmelk B, Irimura T, Geijtenbeek TB, Blixt O, Alvarez R, van Die I, van Kooyk Y. Carbohydrate profiling reveals a distinctive role for the C-type lectin MGL in the recognition of helminth parasites and tumor antigens by dendritic cells. Int Immunol. 2005; 17:661-669.
13. Higashi N, Fujioka K, da-Nagai K, Hashimoto S, Nagai S, Sato T, Fujita Y, Morikawa A, Tsuiji M, Miyata-Takeuchi M, Sano Y, Suzuki N, Yamamoto K, et al. The macrophage C-type lectin specific for galactose/ N-acetylgalactosamine is an endocytic receptor expressed on monocyte-derived immature dendritic cells. J Biol Chem. 2002; 277:20686-20693.
14. van Vliet SJ, Gringhuis SI, Geijtenbeek TB, van Kooyk Y. Regulation of effector T cells by antigen-presenting cells via interaction of the C-type lectin MGL with CD45. Nat Immunol. 2006; 7:1200-1208.
15. Schumacher U, Adam E. Lectin histochemical HPA-binding pattern of human breast and colon cancers is associated with metastases formation in severe combined immunodeficient mice. Histochem J. 1997; 29:677-684.
16. Lescar J, Sanchez JF, Audfray A, Coll JL, Breton C, Mitchell EP, Imberty A. Structural basis for recognition of breast and colon cancer epitopes Tn antigen and Forssman disaccharide by Helix pomatia lectin. Glycobiology. 2007; 17:1077-1083.
17. Saeland E, van Vliet SJ, Backstrom M, van den Berg V, Geijtenbeek TB, Meijer GA, van Kooyk Y. The C-type lectin MGL expressed by dendritic cells detects glycan changes on MUC1 in colon carcinoma. Cancer Immunol Immunother. 2007; 56:1225-1236.
18. Madsen CB, Petersen C, Lavrsen K, Harndahl M, Buus S, Clausen H, Pedersen AE, Wandall HH. Cancer associated aberrant protein O-glycosylation can modify antigen processing and immune response. PLoS One. 2012; 7:e50139.
19. van Vliet SJ, van Liempt E, Geijtenbeek TB, van Kooyk Y. Differential regulation of C-type lectin expression on tolerogenic dendritic cell subsets. Immunobiology. 2006; 211:577-585.
20. van Vliet SJ, Bay S, Vuist IM, Kalay H, Garcia-Vallejo JJ, Leclerc C, van Kooyk Y. MGL signaling augments TLR2- mediated responses for enhanced IL-10 and TNF-alpha secretion. J Leukoc Biol. 2013; 94:315-323.
21. Li D, Romain G, Flamar AL, Duluc D, Dullaers M, Li XH, Zurawski S, Bosquet N, Palucka AK, Le GR, O'Garra A, Zurawski G, Banchereau J, et al. Targeting self- and foreign antigens to dendritic cells via DC-ASGPR generates IL-10-producing suppressive CD4+ T cells. J Exp Med. 2012; 209:109-121.
22. van Vliet SJ, Vuist IM, Lenos K, Tefsen B, Kalay H, Garcia-Vallejo JJ, van Kooyk Y. Human T cell activation results in extracellular signal-regulated kinase (ERK)- calcineurin-dependent exposure of Tn antigen on the cell surface and binding of the macrophage galactose-type lectin (MGL). J Biol Chem. 2013; 288:27519-27532.
23. Belt EJ, Brosens RP, Delis-van Diemen PM, Bril H, Tijssen M, van Essen DF, Heymans MW, Belien JA, Stockmann HB, Meijer S, Meijer GA. Cell cycle proteins predict recurrence in stage II and III colon cancer. Ann Surg Oncol. 2012; 19:S682-S692.
24. Belt EJ, Fijneman RJ, van den Berg EG, Bril H, Delisvan Diemen PM, Tijssen M, van Essen HF, de Lange-de Klerk ES, Belien JA, Stockmann HB, Meijer S, Meijer GA. Loss of lamin A/C expression in stage II and III colon cancer is associated with disease recurrence. Eur J Cancer. 2011; 47:1837-1845.
25. Samowitz WS, Curtin K, Ma KN, Schaffer D, Coleman LW, Leppert M, Slattery ML. Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level. Cancer Epidemiol Biomarkers Prev. 2001; 10:917-923.
26. Piller V, Piller F, Cartron JP. Comparison of the carbohydrate- binding specificities of seven N-acetyl-Dgalactosamine- recognizing lectins. Eur J Biochem. 1990; 191:461-466.
27. Carragher LA, Snell KR, Giblett SM, Aldridge VS, Patel B, Cook SJ, Winton DJ, Marais R, Pritchard CA. V600EBraf induces gastrointestinal crypt senescence and promotes tumour progression through enhanced CpG methylation of p16INK4a. EMBO Mol Med. 2010; 2:458-471.
28. Gill DJ, Tham KM, Chia J, Wang SC, Steentoft C, Clausen H, Bard-Chapeau EA, Bard FA. Initiation of GalNAc-type O-glycosylation in the endoplasmic reticulum promotes cancer cell invasiveness. Proc Natl Acad Sci U S A. 2013; 110:E3152-E3161.
29. Freire T, Lo-Man R, Bay S, Leclerc C. Tn glycosylation of the MUC6 protein modulates its immunogenicity and promotes the induction of Th17-biased T cell responses. J Biol Chem. 2011; 286:7797-7811.
30. Gulubova MV, Ananiev JR, Vlaykova TI, Yovchev Y, Tsoneva V, Manolova IM. Role of dendritic cells in progression and clinical outcome of colon cancer. Int J Colorectal Dis. 2012; 27:159-169.
31. Mansfield AS, Heikkila P, von Smitten K, Vakkila J, Leidenius M. Metastasis to sentinel lymph nodes in breast cancer is associated with maturation arrest of dendritic cells and poor co-localization of dendritic cells and CD8+ T cells. Virchows Arch. 2011; 459:391-398.
32. Nollau P, Wolters-Eisfeld G, Mortezai N, Kurze AK, Klampe B, Debus A, Bockhorn M, Niendorf A, Wagener C. Protein domain histochemistry (PDH): binding of the carbohydrate recognition domain (CRD) of recombinant human glycoreceptor CLEC10A (CD301) to formalinfixed, paraffin-embedded breast cancer tissues. J Histochem Cytochem. 2013; 61:199-205.
33. Xu M, Du X, Liu M, Li S, Li X, Fu YX, Wang S. The tumor immunosuppressive microenvironment impairs the therapy of anti-HER2/neu antibody. Protein Cell. 2012; 3:441-449.
34. Ju T, Lanneau GS, Gautam T, Wang Y, Xia B, Stowell SR, Willard MT, Wang W, Xia JY, Zuna RE, Laszik Z, Benbrook DM, Hanigan MH, et al. Human tumor antigens Tn and sialyl Tn arise from mutations in Cosmc. Cancer Res. 2008; 68:1636-1646.
35. Yoo NJ, Kim MS, Lee SH. Absence of COSMC gene mutations in breast and colorectal carcinomas. APMIS. 2008; 116:154-155.
36. Raman J, Guan Y, Perrine CL, Gerken TA, Tabak LA. UDPN- acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferases: completion of the family tree. Glycobiology. 2012; 22:768-777.
37. Li Z, Yamada S, Inenaga S, Imamura T, Wu Y, Wang KY, Shimajiri S, Nakano R, Izumi H, Kohno K, Sasaguri Y. Polypeptide N-acetylgalactosaminyltransferase 6 expression in pancreatic cancer is an independent prognostic factor indicating better overall survival. Br J Cancer. 2011; 104:1882-1889.
38. Wu C, Guo X, Wang W, Wang Y, Shan Y, Zhang B, Song W, Ma S, Ge J, Deng H, Zhu M. N-Acetylgalactosaminyltransferase-14 as a potential biomarker for breast cancer by immunohistochemistry. BMC Cancer. 2010; 10:123.
39. Guda K, Moinova H, He J, Jamison O, Ravi L, Natale L, Lutterbaugh J, Lawrence E, Lewis S, Willson JK, Lowe JB, Wiesner GL, Parmigiani G, et al. Inactivating germ-line and somatic mutations in polypeptide N-acetylgalactosaminyltransferase 12 in human colon cancers. Proc Natl Acad Sci U S A. 2009; 106:12921-12925.
40. Peng RQ, Wan HY, Li HF, Liu M, Li X, Tang H. MicroRNA-214 suppresses growth and invasiveness of cervical cancer cells by targeting UDPN- acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 7. J Biol Chem. 2012; 287:14301-14309.
41. Park JH, Nishidate T, Kijima K, Ohashi T, Takegawa K, Fujikane T, Hirata K, Nakamura Y, Katagiri T. Critical roles of mucin 1 glycosylation by transactivated polypeptide N-acetylgalactosaminyltransferase 6 in mammary carcinogenesis. Cancer Res. 2010; 70:2759-2769.
42. Gill DJ, Chia J, Senewiratne J, Bard F. Regulation of O-glycosylation through Golgi-to-ER relocation of initiation enzymes. J Cell Biol. 2010; 189:843-858.
43. Ribas A, Wolchok JD. Combining cancer immunotherapy and targeted therapy. Curr Opin Immunol. 2013; 25:291-296.
44. van Vliet SJ, Paessens LC, Broks-van den Berg VC, Geijtenbeek TB, van Kooyk Y. The C-type lectin macrophage galactose-type lectin impedes migration of immature APCs. J Immunol. 2008; 181:3148-3155.
45. Zlobec I, Steele R, Terracciano L, Jass JR, Lugli A. Selecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer. J Clin Pathol. 2007; 60:1112-1116.
46. Heagerty PJ, Zheng Y. Survival model predictive accuracy and ROC curves. Biometrics. 2005; 61:92-105.